Sources
Semafor
AstraZeneca announced a 38% jump in annual pretax profits, driven by strong sales of its cancer and immunology treatments. https://t.co/396fhLdov8
AlphaSense $PM Guidance: "For the first quarter of 2025, we expect a strong start to the year with net revenue and operating income growth, broadly in line with our full year objectives despite the mid-year comparison. We forecast HTU adjusted IMS growth of around plus 10%, which factors… https://t.co/XS0subleg2
- AlphaSense
$AZN Guidance: "Today, we issued guidance for 2025 and expect total revenue to increase by a high single-digit percentage and core EPS to increase by low double-digit percentage. We anticipate our strong growth momentum to continue in 2025, more than offsetting the headwinds… https://t.co/Xtyi8VL5ET
